clinical trial · NCT06735248
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years
ModernaTX, Inc.·phase2·recruiting·n = 180
Multiple SclerosismRNA-1195Placebo
brief summary
The primary objective of this trial is to evaluate the safety and reactogenicity of mRNA-1195 in participants with multiple sclerosis.
started
Apr 16, 2025
primary completion
Jan 8, 2029
completion
Jan 8, 2029
last updated
Dec 22, 2025
official title
A Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of mRNA-1195 Intramuscular Injection in Participants 18 to ≤55 Years of Age With Multiple Sclerosis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol